At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 91 enrolled
Drug / intervention
GSK1755165; placebo; zopiclonedrug
Likely dose
GSK1755165; placebo; zopiclone 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Double-dummy, Placebo-controlled, 3-way Crossover Study to Evaluate Potential Next-day Residual Effects of a Single Evening Dose of 3mg Eszopiclone and 7.5mg Zopiclone in Healthy Adult Subjects.
In Brief
A Phase 3 clinical trial evaluating GSK1755165; placebo; zopiclone for Healthy Subjects and Sleep Initiation and Maintenance Disorders. Completed, enrolled 91 participants across 1 site.
Detailed Summary
This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJul 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedJun 18, 2008
Enrollment StartJul 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.0 years ago
Interventions
GSK1755165; placebo; zopiclonedrug
Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone